Allergy and immunology

Icon
ENTEROSORPTION AS AN IMPORTANT METHOD OF THE ALLEVIATION OF CHRONIC ENDOTOXIN AGGRESSION, 2007

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]

Chernikhova EA, Anikhovskaia IA, Gataullin IuK, Zakirova DZ, Ivanov VB, Savel'ev AA, Iakovlev MIu.

The study of 25 patients with chronic inflammatory diseases (HID) in stage of remission has demonstrated efficiency of intestinal absorption method (enterosorption) to reduce significantly the total concentration of bacterial lipopolysaccharide (LPS) in the general circulation.
[/su_expand]

Icon
Effects of Melatonin, Aluminum Oxide, and Polymethylsiloxane Complex on the Expression of LYVE-1 in the Liver of Mice with Obesity and Type 2 Diabetes Mellitus, 2016

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]

S. V. Michurina, I. Yu. Ishchenko, S. A. Arkhipov, V. V. Klimontov, L. N. Rachkovskaya, V. I. Konenkov, and E. L. Zavyalov

Non-alcoholic fatty liver disease is one of the most common complications of obesity and type 2 diabetes mellitus (DM2). The structural trace of metabolic changes in the liver during the development of obesity and DM2 is largely determined by the status of sinusoidal cells involved in the formation of the blood — lymph barrier, including epithelial, Kupffer, Ito, and Pit cells [1]. Endothelial cells of hepatic sinusoids express the lymphatic vessel endothelial hyaluronan receptor marker LYVE-1 [10]. The expression of LYVE-1 in the liver in DM2 and the relationship between LYVE-1 expression and structural and functional changes in the hepatic vessels are not been studied.
[/su_expand]

Icon
ENTEROSOBTION IN PAEDIATRIC PRACTICE: SELECTION OF OPTIMAL SORBENT, 2010

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]N.V. Nagornaya, M.P. Limarenko, M. Gorky National Medical University of Donetsk

In such a manner, Enterosgel® improves the efficiency of treatment of allergic diseases, due to the following mechanisms: 1) normalizes the function of the digestive tract and immune system; 2) restores the normal composition of intestinal microflora; 3) reduces antigenic load on the digestive system and immune barrier of the intestine; 4) reduces the level of sensitization; 5) binds food and non-food allergens in the digestive tract; 6) reduces the severity and duration of exacerbation of skin and respiratory allergies, increases the duration of remission and reduces the number of relapses.
[/su_expand]

Icon
A MODERN VIEW ON THE ISSUE OF ENTEROSORPTION: CHOOSING THE OPTIMAL DRUG, 2008

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]I. G. Paliy, I. G. Reznichenko

Enterosgel also exhibits selectivity towards microorganisms as it actively binds pathogenic and opportunistic microflora though does not inhibit the normal microflora, thus eliminating intestinal dysbiosis.

[/su_expand]

Icon
ENTEROSGEL COLUMBIA LECTURE, 2016 (Part 1)

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]A.V.Khovanov
Innovative Gastro-absorption method. A novel cleansing system in prevention and treatment.
[/su_expand]

Icon
ENTEROSGEL COLUMBIA LECTURE, 2016 (Part 2)

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]A.V.Khovanov
Innovative Gastro-absorption method. A novel cleansing system in prevention and treatment.
[/su_expand]

Icon
ENTEROSORBENT ENTEROSGEL IN CLINICAL PRACTICE, 2016

T. Miksa

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]ln order to assess the characteristics of the medical device ENTEROSGEL, establish the method of its use and the safety for users, this report was drawn up in the form of a critical evaluation of the relevant
published clinical studies conducted with ENTEROSGEL and with other at least partially comparable
medical devices already placed on the European market.

-Translation from the Czech language-[/su_expand]

Icon
EFFICIENCY OF ENTEROSGEL IN CORRECTION OF SYSTEMIC ENDOTOXEMIA IN CHILDREN WITH ATOPIC DERMATITIS, 2016

T.G. Malanicheva, B.A. Shamov

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]Endotoxin aggression is developed with the expressed release of endotoxin (ET) in the bloodstream on the background of insufficient activity of excretory systems and is qualified as a universal mechanism involved in the pathogenesis of many infectious and non-infectious diseases [1]. Systemic endotoxemia can develop as a result of both inactive intestinal microbiota, constant permeability disorders of the intestinal mucous membranes, and pancreatic insufficiency, biliary duct insufficiency, depression of liver barrier function or reduced portal blood flow, etc [2]. ET presence affects immunocompetent blood cells and is one of the considerable stimulation factors of the immune system. Under physiological conditions, anti-endotoxin antibodies are released in response to ET presence [3]. In pathological endotoxemia a decline of adaptive capacity and body resistance takes place [4, 5]. It is also known that endotoxemia causes cellular hypoxia, metabolic disorders, activation of sympathetic nervous system, complement system, resulting in lysis of leukocytes and platelet aggregation with the release of biologically active substances - kinins, histamine, serotonin, causing "mediator chaos."

All of the above has allowed us to make an assumption about the importance of systemic endotoxemia and endotoxin aggression in atopic dermatitis (AD) in children.

Objective: to define level of systemic endotoxemia in children with AD and evaluate drug Enterosgel (polymethylsiloxane polyhydrate) in complex therapy of the pathology.[/su_expand]

Icon
SAFETY DATA SHEET

Bioline Products s.r.o.

Icon
ABOUT EXPERIMENTAL PRECLINICAL SAFETY STUDYING OF THE MEDICINAL FORM OF A PREPARATION «ENTEROSGEL®,PASTE FOR INTAKE (SWEET)» GIVEN «TNK SILMA LTD.» (MOSCOW), 2010

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]THE STUDY DRUG SAFETY OF "ENTEROSGEL®, PASTA FOR INTAKE (SWEET)" ALLOWS TO RECOMMEND ITS SUBMISSION TO THE TO THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION AS LOW-TOXICITY DRUG AS THE PROCEDURE FOR EXPANDING INDICATIONS AND CHANGES IN INSTRUCTION FOR USE. [/su_expand]


Please rate this information
  • 0/5
  • 0 ratings
0 ratingsX
Very bad! Bad Hmmm Oke Good!
0% 0% 0% 0% 0%